Clexio Biosciences’ Post

Always exciting, the Spring #AAD meeting gives us opportunities network and to reconnect with friends and colleagues. As a forum for information exchange, the meeting is overwhelming with multiple simultaneous sessions and massive plenaries. For me, the most interesting sessions are the Late-Breaking Research Sessions. Seeing the effect of new pathways – Brunton’s tyrosine kinase inhibition for #HidradenitisSuppurativa, increases our understanding of the drivers of #HS. It is always exciting to see further development of new compounds – ESK-001, JNJ-77242113, delgocitinib, ritlecitinib, prepocitinib, povorcitinib, B-VEC, ICP-332, amlitelimab, lutikizumab, sonelokimab, nemolizumab, deuruxoltinib, benvitimod, SHR0302. Keep up the good work. #AAD2024 #dermatology #clinicalresearch #drugdevelopment

🌟 Exciting News from Symmetron! 🌟 📢 The 2023 update of the EULAR recommendations for psoriatic arthritis (PsA) management have arrived with new guidelines, including 7 overarching principles and 11 recommendations driven by developments in drug safety and efficacy. A special shoutout to our Symmetron colleagues for authoring the network meta-analysis (NMA) cited as providing the key comparative efficacy evidence for biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs). 👏 Join us in celebrating these advancements for better patient outcomes. 📈 🔗 Follow the link in the comments to dive into the details! 🔗 #HEOR #Research #Dermatology

In recognition of #MelanomaAwarenessMonth, AMLo Biosciences are sharing (to US-only audience) a patient case study demonstrating the clinical utility of their #AMBLor technology that accurately stratifies early-stage, low-risk melanomas. https://lnkd.in/eehgYpVY AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

PEGASUS’ was a randomised double blind placebo controlled #trial of a Bruton Tyrosine Kinase Inhibitor (BTKI) in pemphigus. Rilzabrutinib is a reversible BTKI. In this global study, new onset and recalcitrant pemphigus vulgaris (PV-90%) and foliaceus (PF-10%) patients were treated with medium doses of prednisone (o.5 mg/kg/d) and randomised to rilza vs placebo. The primary outcome was the proportion of PV patients in Complete remission (no lesions- PDAI zero for at least 8 weeks) on minimal therapy at week 37. In this original protocol, p<0.05 but the trial was completed during the pandemic and FDA mandated excluding patients with remote visits and that minimal therapy be increased to 10mg/d pred; with these restrictions, p>0.05. Murrell et al https://lnkd.in/dNg8iNrU #derm #RCT #pemphigus #rilzabrutinib #clinicaltrial #phase3 #outcomes #PDAI #safety #international #dermatology #principiabio #sanofi #BTKI The PEGASUS study was conducted from January 8, 2019 through October 8, 2021, in 19 countries (Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Poland, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom, and United States).

The latest #psoriasis slide decks are now available on the #IMIDForum! Explore new insights and data to enhance your practice with the top research in #dermatology: [LINK] This month’s Literature Highlights are now available on the Immune-Mediated Inflammatory Disease Forum! November’s single slide summary includes a study by Huang, et al., where they aimed to identify predictors and construct a predictive model for time to relapse following withdrawal from biologics. Find out more about this publication, and more about #psoriasis on the IMID Forum today. 🔗https://ow.ly/z06850UhCMV

Happy 10th anniversary, CAGE! In 2014, we reported the invention of ionic liquid Choline Geranate (CAGE). Since its first report in 2014, CAGE has opened multiple drug delivery applications including transdermal, oral, buccal, sustained release, tissue ablation, periodontitis and hand hygiene, among others. CAGE-based products have been tested in more than 200 patients through multiple Phase 1 and Phase 2 clinical studies, including a successful use in a Phase 2 clinical study in Atopic Dermatitis patients. CAGE became the first ‘drug delivery ionic liquid’ to enter into clinical trials. Check out this recent #openaccess article in the journal of Controlled Release Society that summarizes the key advances and translational aspects of #CAGE as pertained to its use in drug delivery. https://lnkd.in/eqbCQpFU It’s a result of a dedicated effort from a group of researchers to make scientific advances and the CAGE Bio Inc. team to make translational advances! Nitin Joshi Srinivas Sripada Carmine Durham Justin M Ko Marina Shevachman Ravi Srinivasan Shashwati Godbole UC Santa Barbara UCSB Office of Technology & Industry Alliances (TIA) CAGE Bio Inc. #dermatology #ionic_liquids #deep_eutectics

Androgenetic alopecia, which affects both men and women, is hair loss influenced by genetic and hormonal factors. It can lead to a significant drop in body satisfaction and quality of life. At present, treatment options are limited, with treatments such as minoxidil and finasteride, which can slow hair loss, but do not necessarily restore original hair density.   Eurofins bioskin is present in AGA research, with proven expertise: ◾ +20 years' experience in AGA clinical trials ◾ 2000 patients treated, with men and women in our specialized clinical units ◾ Supervision by experienced dermatologists and physicians ◾ Mastery of validated TrichoLAB ® and Canfield systems, for precise analysis of hair growth ◾ Ability to manage complex studies on multiple forms of alopecia areata ◾ Exclusive database and rapid recruitment process for large volumes of patients   Learn more about our services ➡ https://lnkd.in/eK7JN9RE   #Eurofins #bioskin #Alopecia #ClinicalTrials #Innovation #Dermatology

Congratulations to Jannik Rousel, for successfully defending his PhD thesis on October 24, 2024! Jannik’s research introduces non-invasive technologies to enhance early clinical trials for chronic skin diseases like dermatitis and psoriasis. Chronic skin diseases impact 20% of the global population while treatments remain insufficient. His thesis demonstrates data-driven methods that improve decision-making in drug development, including advanced diagnostic tools in a dermatitis trial, increased confidence in clinical outcomes, and the identification of ceramides as a key biomarker for skin barrier health. Well done, Jannik, on this contribution to advancing skin disease research and advancements in early clinical decision-making!  Find his thesis here: https://lnkd.in/ezkrhm9Z #PhDDefense #dermatology #Skindiseases #ClinicalResearch 

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx

I'm excited to share that our recent review article "Laser-mediated solutions: breaking barriers in transdermal drug delivery" has been published. Laser devices, as novel drug delivery systems, have been studied for their positive impact on drug absorption by creating microchannels through the epidermis, referred to as microthermal treatment zones (MTZs). By customizing laser parameters, CO2 and erbium-doped yttrium aluminum garnet (Er:YAG) lasers can be widely used in skin-related problems. In this article, we provide an overview of utilizing lasers as a drug delivery system for complications such as basal cell carcinoma, alopecia, and concerns related to laser use. I am appreciative of the assistance provided by Dr.Ashkan Barfar for valuable guidance, @Abolfazl Afaghmehr and @Niloofar Heydari for their efforts throughout the process, and Dr.Javad Shokri for steering this work as the corresponding author. Special thanks to the reviewers and editors of the AAPS PharmSciTech journal for shaping this article with their guidance. Link: https://rdcu.be/dLwKC #Laser, #transdermal, #novel, #dermatology, #derm, #drug_delivery, #drug_delivery_system, #laser_assisted_drug_delivery